Familial Hypercholesterolemia and Lipoprotein Apheresis
Author:
Affiliation:
1. Department of Diabetes and Lipid Metabolism, National Cerebral and Cardiovascular Center
2. Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute
Publisher
Japan Atherosclerosis Society
Subject
Biochemistry (medical),Cardiology and Cardiovascular Medicine,Internal Medicine
Link
https://www.jstage.jst.go.jp/article/jat/26/8/26_RV17033/_pdf
Reference52 articles.
1. 1) Goldstein JL and Brown MS: The metabolic basis of inherited disease. MacGraw-Hill, New York, NY, 1982
2. 2) Santos RD, Gidding SS, Hegele RA, Cuchel MA, Barter PJ, Watts GF, Baum SJ, Catapano AL, Chapman MJ, Defesche JC, Folco E, Freiberger T, Genest J, Hovingh GK, Harada-Shiba M, Humphries SE, Jackson AS, Mata P, Moriarty PM, Raal FJ, Al-Rasadi K, Ray KK, Reiner Z, Sijbrands EJ, and Yamashita S: Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International atherosclerosis society severe familial hypercholesterolemia panel. Lancet Diabetes Endocrinol, 2016; 4: 850-861
3. 3) Illingworth DR: How effective is drug therapy in heterozygous familial hypercholesterolemia? Am J Cardiol, 1993; 72: 54d-58d
4. 4) Harada-Shiba M, Sugisawa T, Makino H, Abe M, Tsushima M, Yoshimasa Y, Yamashita T, Miyamoto Y, Yamamoto A, Tomoike H, and Yokoyama S: Impact of statin treatment on the clinical fate of heterozygous familial hypercholesterolemia. J Atheroscler Thromb, 2010; 17: 667-674
5. 5) Raal FJ, Hovingh GK, Blom D, Santos RD, Harada-Shiba M, Bruckert E, Couture P, Soran H, Watts GF, Kurtz C, Honarpour N, Tang L, Kasichayanula S, Wasserman SM, and Stein EA: Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Lancet Diabetes Endocrinol, 2017; 5: 280-290
Cited by 33 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. How can we improve the prognosis of patients with homozygous familial hypercholesterolemia?;Atherosclerosis;2024-04
2. Research Progress in the Clinical Treatment of Familial Hypercholesterolemia;Current Medicinal Chemistry;2024-03
3. Facile Preparation of β-Cyclodextrin-Modified Polysulfone Membrane for Low-Density Lipoprotein Adsorption via Dopamine Self-Assembly and Schiff Base Reaction;Materials;2024-02-21
4. Treating PAD Patients with Lipoprotein Apheresis;Journal of Atherosclerosis and Thrombosis;2024
5. Lipoprotein Apheresis Alleviates Treatment-Resistant Peripheral Artery Disease Despite the Normal Range of Atherogenic Lipoproteins: The LETS-PAD Study;Journal of Atherosclerosis and Thrombosis;2024
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3